The group, which argues that opioid labeling is overly broad, is pushing for the FDA to remove the word “moderate” from the description that describes drugs as approved for “moderate to severe pain.”
Among those who signed the petition are members of Physicians for Responsible Opioid Prescribing and physicians or researchers with the New York City Health Commissioner, the Cleveland Clinic and the Mayo Clinic.
Related Articles on Pain Management:
Orexo Seeks FDA Approval for Opioid Dependency Drug
Nektar Launches Phase 2 Study for Chronic Pain Drug
Relmada Raises $3M to Develop LevoCap Painkiller
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.